ClinicalTrialsFinder
RecruitingPhase 1NCT05335811

First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging

Sponsor

M.D. Anderson Cancer Center

Enrollment

55 participants

Start Date

Oct 6, 2022

Study Type

INTERVENTIONAL

Conditions

Endocrine Neoplasia

Summary

18F-4FN represents a novel PET agent for imaging inflammation. Acute inflammatory signaling through the TLR axis recruits neutrophils and macrophages to inflammatory sites. Both cells activate the production of high energy reactive oxygen species/reactive nitrogen species (RONS), setting off a cascade that can be leveraged to detect the presence of these inflammatory cells by molecular imaging. 18F-4FN is efficiently oxidized by high energy RONS, leading to retention and accumulation in human neutrophil-like cells in vitro, and at the sites of acute inflammation in vivo. Like 18F-FDG, 18F-4FN clears rapidly through the kidney at 1 hr following i.v. injection

Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Patient >/= 18 years of age.
  • Patients with histologic diagnosis of solid or liquid tumor treated by ICI with evidence of or clinical suspicion of irAE or patients with suspected inflammation.
  • Normal range standard renal and liver function tests for age:
  • eGFR >= 60 mL/min/1.73 m2
  • Adequate liver function:
  • Bilirubin ≤ the upper limit of normal (ULN) Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ the ULN

Exclusion Criteria5

  • Pregnant or lactating women: pregnant women are excluded from this study because the effects of \[18F\]4FN in pregnancy are not known. Urine or serum pregnancy test (female </= 60 years of age or childbearing potential) within 24 hours of the PET scan.
  • Subjects with contraindications to the use of \[18F\]4FN including confirmed allergy.
  • Patients with a body weight of 400 pounds or more, or a BMI which precludes their entry into the bore of the PET/CT scanner, because the hardware is not intended to support that weight.
  • Any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the physician may significantly interfere with study compliance.
  • Children below the age of 18 are excluded because of the unknown but potential risk of administration of radiopharmaceuticals to minors.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG4-[18F]Fluoro-1-Naphthol

By vein (IV)

Locations(1)

MD Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05335811